Today, payers demand more and better evidence of precise costs and benefits new drugs provide. While obtaining market authorization is a sponsor’s top priority, obtaining reimbursement and market access is equally challenging in today’s landscape. However, it can be difficult to design a drug-development program that meets the requirements of regulators and payers.
